AI assistant
Axogen, Inc. — Director's Dealing 2022
Apr 1, 2022
32414_dirs_2022-04-01_962fa57d-cf36-4f04-aff4-15ad3fc3e217.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Axogen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2022-03-30
Reporting Person: Blackford Quentin S. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-30 | Common Stock | M | 3036 | — | Acquired | 27335 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-30 | Restricted Stock Units | $ | M | 3036 | Disposed | Common Stock (3036.0) | Direct |
Footnotes
F1: This reflects the number of restricted stock units that became vested as of March 30, 2022.
F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F3: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. This grant was accelerated by Axogen's Board of Directors to vest upon departure.